Stress, Proinflammation, Autoregulation and Cardiovascular Diseases

Stress, Proinflammation, Autoregulation and Cardiovascular Diseases

Chronic stress can be an extremely detrimental phenomenon because it maintains an artificial state of excitation, whereas acute stress ends this process in a more timely manner. Therefore, it is not surprising to find proinflammatory phenomena occurring during chronic stress since the system maintains excitability, including that of immune origin.

The cardiovascular system is also subject to the excitatory influence of chronic stress and it maintains an activation state far exceeding the purpose of this response, i.e., oxygen and nutrient delivery to tissues. Regarding the stress response, we surmise that this cellular, tissue and organismic activation is shut off normally by way of cascading chemical messengers designed to terminate the response. Here, based on empirical evidence, we speculate that endogenous morphine via stereoselective opiate receptors (μ3-4) coupled to constitutive nitric oxide release is part of a down regulatory mechanism, assisting in terminating a stress response if appropriate. Indeed, the enzymes capable of synthesizing morphine are subject to variations, which may, in part, account for the detrimental effects of chronic stress since the process cannot now be terminated easily given that the morphinergic signaling may be subject to insufficiency. Taken together, this speculative review attempts to provide novel answers to an old problem.


Proinflammation is a widespread phenomenon as is stress. Proinflammation is potentially associated with the stress pathophysiology and therefore may be connected with various stress-related, as well as stress-unrelated diseases [1], [2,3]. Moreover, proinflammation possesses a close correlation , e.g., with type 1 immune response pathways [1], [4,5].  Stress also modifies these immune response pathways, e.g., type 1 and type 2 modulation [4]. Hence, proinflammation can be identified as a common denominator in various disease states and as a ‘common ground’ of distinct pathological states, yet interconnected on the molecular level [2-4]. However, the association of proinflammation with stress and cardiovascular disease processes has only recently emerged in the scientific focus.

Like stress, proinflammation seems to represent a crucial autoregulatory concept. This is not astonishing since proinflammation normally serves a positive biological goal. Proinflammatory activities, for example, are initiated to overcome infection or invasion of potentially deleterious biological agents (bacteria, viruses, parasites etc.). Moreover, while fighting invasion, proinflammation – if successfully implemented – usually shortens biological ”battles” and therefore ameliorates disease-related or subjectively unpleasing phenomena. However, proinflammation has to be stopped and terminated in time, that is, (auto)regulated and controlled. This can become a problem due to the actual invader or biological threat that is encountered, or to a possible deterioration of the underlying self-control mechanisms. Thus, proinflammation can serve in both beneficial and deteriorating capacities [2]. The specific outcome that emerges is critically linked, e.g., to the state of the immune or cardiovascular system and its molecular and stress-related processes that emerge under pressure or perturbation [1-3]. Stress autoregulation and the molecular processes that build this capacity, therefore, have now moved into the scope of the biological and medical sciences.


Stress is a natural, biological and, at times, useful phenomenon. Stress describes the effects of psychosocial and environmental factors on physical and/or mental well-being [1,6,7]. Stress implies a challenge that requires behavioral, psychological, and physiological changes (adaptations) to be successfully met, therefore using a state of hyperarousal for the initiation of necessary counteracting reactions [1,6-9]. This state of hyperarousal involves physiological mechanisms that are known as the stress or ‘fight-or-flight’ response, a set of physiological changes that occur in stressful situations and that prepare the stressed organism either to fight or to flee. This state of alertness was first described by Walter Cannon almost a century ago [10-12]. Years later, Hans Selye, among others, refined the physiological stress concept and its significance for biology and survival [6,7]. Modern concepts and recent studies have eventually associated the stress theory with human ailments and its neurobiological implications [8,9,13-18].

Stress occurs when we meet a sudden challenge and are forced to act/react in order to survive or to endure. When a zebra unexpectedly meets a lion, its physiology turns towards alarm, i.e., fight or flight, or eventually ‘freeze’, when the challenge is simply overwhelming implying a physiological black out [13,15,16]. Every bodily or mental activity is now scanned for the usefulness or deleteriousness in responding to the challenge, the stressor. Beneficial mechanisms will be enforced other mechanisms will be shut-down. This is natural and, at times, helpful, although there are exceptions. Following a successful escape or fight, the body naturally recovers and the mind relaxes. Autoregulatory messengers and signaling molecules effortlessly enable this rebound or recreational state [13].

However, problems may occur when stress endures for too long, is too massive or the physiology not suitably fitted to fight a particular stressor, or when enough time for recovery is not allowed [1-6,9,13,19-21]. In addition, at the organismic level, the biochemical response machinery responsible for turning off a stress reaction may be damaged. This seems to be a real human dilemma equipped with the very same stress response mechanisms that the zebra fortunately possesses, we usually don’t have to oppose life-threats in forms of lions or other external enemies in our daily life [15,16,20,22].

Thus, we start to think about the stresses and dangers in the future, the stressors and potentially stressful situations that might come, or the things that we encountered in the past, regarded as stressful [1]. Furthermore, we may start to dwell about our potentially suboptimal coping and resistance capacities in the present, thereby diminishing these very same capacities, causing us self-inflicted stress and impairment of our defense, i.e., ‘cognitive constipation’ [1]. This useful and helpful mechanism that was designed to help us cope with stressors may become deleterious, and stress-related diseases consequently emerge [4,17,23]. This is the critical path that underlies much of modern stress and human stress-related diseases. However, we not only possess the endogenous capacity to self-inflict stress and harm, i.e., self-harm, but also to self-manage it, reduce its impact, be self-efficacious and endogenously heal or prevent stress disorders via stress management [13].

Proinflammation, stress and diseases

Proinflammation is a phenomenon that is involved in many stress-related diseases [1,4]. Stress is important because it represents a common feature of life [1] and it may further trigger the activation of biological immune response pathways, including the proinflammatory type 1 response [4]. However, stress, especially ”adequate” amounts of acute stress (in contrast to ”overwhelming” or chronic stress), usually favors and facilitates type 2 immune response pathways (humoral response) [1,4,24-26].

Proinflammation is a common (patho)physiological state, one that may either exert beneficial (when utilized as an adequate defense mechanism) or detrimental effects (particularly in the long-term, when proinflammation endures) [4]. Numerous cytokines are present within proinflammatory foci. Interleukin (IL)-1 and tumor necrosis factor (TNF) are of particular importance. IL-1 and TNF-alpha play a major role in coordinating mechanisms which command (pro)inflammation [27,28]. Upon their action, many different cells produce lipidic mediators, proteolytic enzymes and free radicals, all directly responsible for the noxious effects detectable and eventually leading to thorough disease processes [28]. IL-1 and TNF exert cytotoxic effects on vascular endothelium, cartilage, bone, muscle, and other tissues [28].

In contrast, soluble TNF receptors, released during inflammation, are the direct inhibitors of TNF. Glucocorticoids, released following a cascade of events initiated by IL-1, TNF-alpha and IL-6, involving the neuroendocrine axis (i.e., stress), also inhibit proinflammatory cytokine productions [2,28]. Thus, feedback mechanisms exist that are set up to keep proinflammation in balance. However, once the proinflammatory pathway gets activated and a prolonged or strong stimulation endangers homeostasis, deteriorating pathophysiological developments may occur. These may manifest themselves in different regions of the body. Thus, different diseases with a common (overlapping) pathophysiological background and similar patterns of cytokine activity may develop.

Recent studies suggest that (pro)inflammation plays a role in the pathogenesis of cardiovascular diseases. Not only in atherosclerosis and coronary artery disease [23] but also in other diseases of the circulatory system, proinflammation may be involved [23,29]. For example, IL-1, TNF-alpha, and mainly IL-6 are the three most important known proinflammatory cytokines involved in the pathogenesis of hemodialysis-related and cardiovascular diseases [29]. Nitric oxide (NO) pathways may further play a role. Also, an elevated blood pressure (i.e., arterial hypertension) may induce an inflammatory state in the arterial wall through both immune response and mechanical signaling pathways [30]. The generation of reactive oxygen species and subsequent up-regulation of redox-sensitive proinflammatory gene products are common endpoints of these pathways [4,23,30].

Atherosclerosis is characterized by a non-specific local inflammatory process which is accompanied by a systemic response [31-33]. A number of prospective studies in initially healthy subjects and in patients with known atherosclerosis have convincingly demonstrated a strong and independent association between even slightly elevated concentrations of various systemic biomarkers of inflammation and a number of cardiovascular events [34,35]. Indeed, the observation that almost half of all myocardial infarctions and strokes occur in persons without elevated levels of low-density lipoprotein (LDL) cholesterol, one of the classical risk factors for cardiovascular diseases, has prompted the search for factors or markers other than hyperlipidemia that contribute to the development or point towards the existence of atherosclerosis.

Evidence indicates that inflammation plays a substantial role in plaque progression and rupture. For instance, C-reactive protein (CRP), the classical acute phase protein, seems to be the marker of choice in this clinical situation [33,36-38]. Moreover, combining LDL and CRP measurements may further increase the explanatory power of related test procedures, i.e., better prognostic information [32,35]. This may be due to the fact that CRP and LDL cholesterol measurements tend to identify different high-risk groups [35]. However, CRP is a stronger predictor of cardiovascular events than the LDL cholesterol level [35]. In addition, recent research has suggested that CRP may not only be a risk factor, but may be directly involved in the pathogenesis of atherosclerosis [33]. This suggestion still has to be investigated further.

However, statins have been shown to reduce levels of CRP through mechanisms independent of their effects on lipid levels [38]. Initial clinical studies also suggest that CRP levels may have utility in the targeting of statin therapy, particularly in primary prevention [38]. These results still need direct and thorough testing to determine whether statin therapy will benefit persons without overt hyperlipidemia but with evidence of systemic inflammation. Also, indications exist that other drugs with positive effects on cardiovascular outcome, e.g., antidiabetic medications, may have antiinflammatory capacities in addition to their actual properties as well. A new ”wave of research” in the field of inflammation/antiinflammation has thus recently been initialized.

Taken together, proinflammatory activity may be regarded as a marker or even risk factor (contributor) of atherosclerosis and may predict severe or fatal myocardial/vascular events [39]. Proinflammation may go along with a number of negative cardiovascular developments, like atherosclerosis, plaque formation and rupture, endothelial dysfunction, etc. [39]. Moreover, certain treatments that reduce coronary risk, e.g. lipid lowering drugs or even stress management strategies (lifestyle modification programs etc.) [40,41], may also limit inflammation [32]. In the case of lipid lowering, the ”innate” antiinflammatory effect does not appear to correlate with reduction in LDL levels alone [32]. These new insights into inflammation in atherosclerosis not only increase our understanding of this disease, but also have practical clinical applications in risk stratification and targeting of therapy for this condition of growing worldwide importance [32].

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the intestine and/or colon of unknown etiology in which patients suffer from severe diarrhea, rectal bleeding, abdominal pain, fever, and weight loss [42,43]. Active episodes of IBD are characterized by vasodilatation, venocongestion, edema, infiltration of large numbers of inflammatory cells, and erosions or ulcerations of the bowel [2,42,43].

It is becoming increasingly apparent that chronic gut inflammation (i.e., IBD) may result from a dysregulated, imbalanced, immune response as evidenced by a sustained overproduction of proinflammatory cytokines and mediators [42]. Many of these T helper (Th)1 and macrophage-derived cytokines and lipid metabolites are known to activate microvascular endothelial cells, thereby promoting leukocyte recruitment into the intestinal interstitium and inflammation [42]. Normally the balance between Th1 and Th2 pathways can be maintained and it is not clear why in IBD this balance is so much endangered (i.e., the susceptibility to proinflammation is enhanced). It is possible a breakdown in protective antiinflammatory components of the immune response initiates chronic gut inflammation [42,44].

The normal intestinal immune system is under a balance in which proinflammatory and antiinflammatory cells and molecules are carefully regulated to promote a normal host mucosal defense capability without destruction of intestinal tissue [4,45]. Once this careful regulatory balance is disturbed, nonspecific stimulation and activation can lead to increased amounts of potentially destructive (pro)inflammatory molecules [2,45]. The concept of balance/homeostasis and regulation of normal mucosal immune and inflammatory events is indicative of how close the intestine is to developing severe inflammation [45].

The intestinal mucosal immune system is constantly stimulated by lumenal contents and bacteria [45]. Highly stimulatory bacterial cell wall products, for example, are capable of activating macrophages and T lymphocytes to release potent proinflammatory cytokines, including IL-1, -6, and TNF-alpha [45]. Hence, these cytokines increase the presence of human leukocyte antigen (HLA) class II antigen-presenting molecules on the surfaces of epithelial cells, endothelial cells, macrophages, and B cells, thus increasing their ability to present lumenal antigens and bacterial products [2,4,45]. The proinflammatory cytokines IL-1 and TNF-alpha also increase the ability of epithelial cells, endothelial cells, macrophages, and fibroblasts to secrete potent chemotactic cytokines, such as IL-8 and monocyte chemoattractant protein 1 (MCP-1), which serve to enhance the movement of macrophages and granulocytes from the circulation into the inflamed mucosa [2,45].

Thus, through lumenal exposure to nonspecific stimulatory bacterial products, the state of activation of the intestinal immune system and mucosal inflammatory pathways become markedly up-regulated [45]. This raises the question of whether there is a deficiency in effective down-regulation through the absence of normally suppressive cytokines such as IL-4, -10, transforming growth factor-beta (TGF-beta), and IL-1 receptor antagonist [4,24,45].

Normally, the turning off of the active and potentially destructive inflammatory events should occur following the resolution of a bacterial or viral infection that has been appropriately defended against and controlled by the mucosal immune system [45]. In IBD, however, the down-regulatory processes that should turn off the inflammatory – intentionally protective – pathways, once the pathogenic agent has been cleared, appear to be deficient or only partially effective [2,45]. Clearly, a high degree of stress-sensitivity may play a significant role here. Again, proinflammation itself represents a reasonable – and most often effective – biological defense mechanism that yet has the capability of becoming detrimental when it cannot be controlled appropriately.

Studies that have investigated IBD have improved our molecular understanding of the pathophysiology of ulcerative colitis and Crohn”s disease [46]. Several proinflammatory and immune-regulatory cytokines are up-regulated in the mucosa of patients with IBD, and similarities in the cytokine profiles of ulcerative colitis and Crohn”s disease have been elucidated [46]. TNF-alpha has been shown to represent a crucial component of the chronic mucosal inflammation that is pathognomonic in IBD and seems to be particularly of importance in the pathogenesis of Crohn”s disease [2,46]. Additionally, substantial concentrations of inducible nitric oxide synthase (iNOS), IL-1, TNF-alpha, and INF-gamma have been detected in inflammatory epithelial cells (inflammatory infiltrate) of ulcerative colitis/Crohn”s disease patients, whereas IL-6 activity seems to be significantly enhanced in the adrenal glands of these patients [47-50]. Thus, (chronic) proinflammation apparently is a fundamental component of IBD.

In infectious and parasitic diseases proinflammatory activities, by nature, are detectable. The defense of microbiological invaders is one of the most urgent and important tasks of proinflammatory immune response pathways. However, proinflammation, and particularly when enduring, chronic, or uncontrolled is also responsible for many negative or detrimental concomitant phenomena and disease processes that accompany the defense of infectious agents. Yet, these ”side effects” of proinflammation itself can become a threat and may even meet the criteria for disease promoting factors (see above). Therefore, we find proinflammatory activity as a common denominator or background underlying devastating pathophysiological mechanisms in various infectious diseases. In this regard, various parasites also attempt to down-regulate the host proinflammatory response to ensure their survival [2,51-53].

Autoimmune diseases have a close association with proinflammatory pathways. In (autoimmune) glomerulonephritis, for example, iNOS activity, TNF-alpha and interferon (IFN)-gamma production have been observed [54]. Rheumatoid arthritis (RA) regularly shows proinflammatory activity. Protective and detrimental NO effects have been observed in RA (iNOS/cNOS activity) [55-58]. Additionally, NF-kappaB activation, proinflammatory cytokine production (IL-1, IL-6, IL-8, TNF-alpha, GM-CSF), hypoactivity of the hypothalamic-pituitary-adrenal (HPA) axis, and an involvement of the sympathetic nervous system (SNS) have been proven [1,2,4,58-60]. Again, stress may be fundamentally involved in proinflammatory pathophysiological developments of importance in RA [2,61]. Here, the crucial step seems to be represented by a chronic synovial inflammation that is related to a state of prolonged proinflammation [2,4,58-61].

In diabetes mellitus type 1, the destruction of the pancreatic islet cells via proinflammatory pathways seems to represent an initial critical step of disease onset/development [62,63]. Also, deleterious proinflammatory NO (iNOS) activity and cytokine production has been detected in pancreatic islet cells/pancreatic islet destructive macrophages of diabetic mammals [64-66]. In addition, proinflammatory IL-6 and TNF-alpha production may promote vascular adhesion [67] and TNF-alpha has been shown to be associated with dyslipidaemia and increased blood pressure adding to an already enhanced vascular disease risk related to type 1 diabetes mellitus [67].  Metabolic syndrome, being overweight, and diabetes mellitus type 2 are associated with (pro)inflammation and elevated serum CRP concentrations as well [2,33]. This correlation strongly supports the hypothesis that atherosclerosis or other cardiovascular diseases (see above) and type 2 diabetes share a common underlying pathophysiology [33].

Recently, we have discussed the significance of immune processes in Alzheimer’s and Parkinson’s disease [68,69]. Indeed, proinflammation-related free radical generation, either contributing to or associated with enhanced immune responsiveness, may be regarded as an initiating factor here [3,68,69]. Hence, neuronal degeneration as detectable, for instance, in Alzheimer’s disease (AD) may be associated with inflammatory processes and these may further be connected with the stress pathophysiology. Proinflammatory elevated IL-6 concentrations have been verified in the brains of AD patients [70]. Thus, IL-6 expression may precede neuronal changes in AD [70]. Moreover, several studies indicate that IL-6 expression is related, for example, to psychosocial stress, and therefore, chronic stress and (pro)inflammation may significantly contribute to the pathophysiology underlying AD and dementia [70]. Taken together, proinflammation apparently is involved in many different pathophysiological disease processes. Moreover, proinflammatory (pre)conditions may serve as an important and common pattern in various diseases.

Immune processes, stress regulation and endogenous morphine

Recently, it was demonstrated that human white blood cells (WBC) and invertebrate ganglia contain and have the ability to synthesize morphine and release it into the microenvironment [71,72]. Additionally, human stem cells were found to contain an opiate subtype receptor mu-3 like or mu-4, which only responds to morphine and is coupled to constitutive NO release as previously described for mu-3 [73,74]. Human vascular endothelial cells contain morphine and have the mu3-NO coupled opiate receptor [73,75]. These studies support earlier studies demonstrating a presence of endogenous morphine and morphine 6 glucuronide in animal tissues, including adrenal [76-86]. Taken together, these studies provide empirical evidence that the synthesis of morphine by various tissues and diverse animals is more widespread than previously thought.

Morphine biosynthesis uses elements of the catecholamine pathway as precursor molecules in its synthesis, such as tyrosine, L-DOPA and dopamine, suggesting that their modulation is critical for endogenous morphinergic processes [72,87,88]. Furthermore, cholinergic nicotinic processes have also been shown to be involved with endogenous morphine processes via novel nicotinic receptors, which can modulate cellular morphine release [89-94]. These results also strongly suggest that these neurotransmitter/neuroimmune chemical messengers exhibit relationships indicative of autocrine and paracrine signaling [95].

Endogenous morphine is synthesized via established and predictable components of the catecholamine pathway [71,72]. Its synthesis and release results in NO release via diverse tissue sources, which serves as a negative feedback modulator, effecting key enzymes in the pathway, such as catechol-O-methyltransferase (COMT), tyrosine hydroxylase (TH) and CYP2D6 [81,84,89,90,92-106]. Interestingly, early on a relationship was found with dopamine, a morphine precursor, and serotonin [107-109]. It appears that gene expression microarray has captured these relationships, which have been validated over the years in diverse animals and tissues.

As is the case for catecholamines, morphine-nitric oxide coupling also appears to be part of stress modulation, i.e., down regulating the stress response [110-114]. Interestingly, endogenous morphine release is enhanced following surgical, environmental, thermal and psychological stressors [79,115-122], suggesting its presence is required to partially mediate the stress response. In this regard, endogenous morphine levels increase post-stress as compared to pre-stress, suggesting a role in terminating the stress response [123-126].

The enzyme phenylethanolamine N-methyltransferase (PNMT) has been suggested to participate in the biosynthesis of morphine [88]. PNMT’s most well studied function is the production of the terminal catecholamine, epinephrine. PNMT is present in high concentrations in the adrenal medulla, but it can also be found in nervous and cardiac tissues [127]. Tissues of the adrenal medulla as well as sympathetic nerves are both derived during development from neural crest cells [128].  PNMT mRNA expression can be up regulated by stress hormones [129]. Similarly, morphine levels are increased by exposure to stress hormones [130], again suggesting that endogenous morphine becomes active post-stress to restore homeostasis. The presence of morphine in an adrenal chromaffin cell line [85] and in rat adrenal glands [131] as well as the secretion of morphine-6-glucuronide by adrenal chromaffin cells [132] suggests the involvement of PNMT, and other enzymes found in the adrenal glands, in morphinergic processes.

Morphine and epinephrine levels can be increased by stress hormones [129,130,133] placing these chemical messengers in an important survival pathway. In rats without pituitary glands, glucocorticoids and dexamethasone stimulated PNMT mRNA production [134]. Conversely, decreased corticosteroids have been linked to decreased PNMT activity [135].  In adrenal glands, glucocorticoids are needed for PNMT expression [127].

Corticotropin releasing hormone knockout mice do not up regulate their PNMT mRNA in response to stress [136]. The presence of normal glucocorticoid signaling may be necessary for a functional morphine biosynthetic system. If PNMT is serving to synthesize morphine as well as epinephrine, there might be multiple forms of this enzyme to perform these actions. Different forms of PNMT mRNA exist in adrenal glands and in cardiac tissue [127]. The heart contains two forms, one containing introns and the other is an intronless message. The adrenal gland only contains the intronless form [127,137]. The intronless form’s expression is increased by dexamethasone and the intron containing form is decreased [137]. In the heart, the intronless message can increase blood pressure, glucose and lymphocyte cytokine production [137]. The PNMT responsible for morphine synthesis has yet to be characterized.


The understanding that chronic stress can enhance and maintain a proinflammatory state links these phenomena. Furthermore, since cardiovascular disorders can also be part of the same stress circuitry and exhibit proinflammatory characteristics, this makes the phenomenon of proinflammation central in our hypothesis. Newer information provides empirical evidence for a major down-regulatory role of endogenous morphine and morphine-nitric oxide coupling in the processes just described, i.e., stress regulation, proinflammation, etc.

Given the dependency of morphine signaling on catecholamine presence raises the issue of morphine insufficiency [110].  In other words, when the brake is missing this uncontrolled level of excitation may attribute to catecholamine activation in stress, in many tissues, and contribute to the pathologies that they manifest, e.g., (un)controlling blood pressure. This appears to be true since gene variations occur in both the catecholamine and morphine synthesis pathways, making some forms of the critical enzymes more efficacious. The introduction of morphinergic signaling as a critical component of stress termination on the tissue and organismic level is a novel hypothesis that has been supported by past empirical data and awaits future studies for further validation.

Nonstandard Abbreviations: CRP, C-Reactive Protein; HPA, Hypothalamic-Pituitary-Adrenal axis; IBD, Inflammatory Bowel Disease; IFN, Interferon; IL, Interleukin; iNOS, Inducible Nitric Oxide Synthase; RA, Rheumatoid Arthritis; Th, T Helper Cell; SNS, Sympathetic Nervous System; TNF, Tumor Necrosis Factor

Author(s) Affiliation

T Esch – Neuroscience Research Institute, State University of New York, College at Old Westbury, NY 11568, USA; Division of Integrative Health Promotion, Coburg University of Applied Sciences, Coburg, Germany
KJ Mantione – Neuroscience Research Institute, State University of New York, College at Old Westbury, NY 11568, USA
GB Stefano – Neuroscience Research Institute, State University of New York, College at Old Westbury, NY 11568, USA


  1. Stefano GB, Benson H, Fricchione GL, Esch T (eds.). The Stress Response: Always Good and When It Is Bad. Medical Science International, New York 2005
  2. Esch T, Stefano GB. Proinflammation: A common denominator or initiator of different pathophysiological disease processes. Med Sci Monit 2002; 8: HY1-9
  3. Esch T, Stefano GB, Fricchione GL, Benson H. Stress-related diseases: A potential role for nitric oxide. Med Sci Monit 2002; 8: RA 103-118
  4. Esch T, Stefano GB, Fricchione GL, Benson H. An overview of stress and its impact in immunological diseases. Mod Asp Immunobiol 2002; 2: 187-192
  5. Esch T, Stefano GB, Fricchione GL, Benson H. Stress-related diseases: A potential role for nitric oxide. In: Stefano GB (ed.). Biomedical significance of nitric oxide. Medical Science International, New York, 2003
  6. Selye H. Implications of stress concept. N Y State J Med 1975; 75: 2139-2145
  7. Selye H. The evolution of the stress concept. Am Sci 1973; 61: 692-699
  8. McEwen BS. Central effects of stress hormones in health and disease: Understanding the protective .and damaging effects of stress and stress mediators. Eur J Pharmacol 2008; 583: 174-18
  9. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171-179
  10. Cannon WB. A note on the effect of asphyxia and afferent stimulation on adrenal secretion. Science 1917; 45: 463-464
  11. Cannon WB, Querido A. The role of adrenal secretion in the chemical control of body temperature. Proc Natl Acad Sci USA 1924; 10: 245-246
  12. Cannon WB, Pereira JR. Increase of adrenal secretion in fever. Proc Natl Acad Sci USA 1924; 10: 247-248
  13. Esch T, Stefano GB. The neurobiology of stress management. Neuroendocrinology Letters 2010; 31: 19-39
  14. McEwen BS. The brain is the central organ of stress and adaptation. Neuroimage 2009; 47: 911-913
  15. Sapolsky RM. Why zebras don’t get ulcers. Owl, USA, 2004
  16. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003; 28: 1735-1742
  17. Esch T, Stefano GB, Fricchione GL, Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuroendocrinol Lett 2002; 23: 199-208
  18. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-284
  19. Esch T. [Stress, adaptation, and self-organization: Balancing processes facilitate health and survival]. Forsch Komplementarmed Klass Naturheilkd 2003; 10: 330-341
  20. Esch T. [Health in stress: Change in the stress concept and its significance for prevention, health and life style]. Gesundheitswesen 2002; 64: 73-81
  21. Metz U, Welke J, Esch T, Renneberg B, Braun V, Heintze C. Perception of Stress and Quality of life in overweight and obese people – Implications for preventive consultancies in primary care. Med Sci Monit 2009; 15: PH1-6
  22. Esch T, Stefano GB. A bio-psycho-socio-molecular approach to pain and stress management. Forsch Komplementmed 2007; 14: 224-234
  23. Esch T, Stefano GB, Fricchione GL, Benson H. Stress in cardiovascular diseases. Med Sci Monit 2002; 8: RA93-RA101
  24. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M: Cytokines and autoantibodies to cytokines. Stem Cells 1995; 13: 206-222
  25. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve – an integrative interface between two supersystems: the brain and the immune system. Pharmacological Reviews 2000; 52: 595-638
  26. Elenkov IJ, Chrousos GP: Stress, cytokine patterns and susceptibility to disease. Bailliere”s Best Practice and Research. Clinical Endocrinology and Metabolism 1999; 13: 583-595
  27. Raman U, Eswaran D, Narayanan RB, Jayaraman K, Kaliraj P: Proinflammatory cytokines secreted by monocytes of filarial patients. Microbiology and Immunology 1999; 43: 279-283
  28. Cavaillon JM: [Cytokines in inflammation]. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales. 1995; 189: 531-544
  29. Panichi V, Migliori M, De Pietro S et al.: The link of biocompatibility to cytokine production. Kidney International. Supplement 2000; 76: S96-S103
  30. Taylor WR: Hypertensive vascular disease and inflammation: mechanical and humoral mechanisms. Current Hypertension Reports 1999; 1: 96-101
  31. Ross R: Atherosclerosis – an inflammatory disease. New England Journal of Medicine 1999; 340: 115-126
  32. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 135-1143
  33. Koenig W, Hoffmeister A, Khuseyinova N, Imhof A: [Atherosclerosis – an inflammatory process]. Deutsches Arzteblatt 2003; 100: A117-126
  34. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2599
  35. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine 2002; 347: 1557-1565
  36. Ridker PM, Hennekens CH, Buring J, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine 2000; 342: 836-843
  37. Ridker PM: High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818
  38. Ridker PM: Connecting the role of C-reactive protein and statins in cardiovascular disease. Clinical Cardiology 2003; 26: III39-44
  39. Nguyen VH, McLaughlin MA: Coronary artery disease in women: a review of emerging cardiovascular risk factors. Mount Sinai Journal of Medicine 2002; 69: 338-349
  40. Koertge J, Weidner G, Elliott-Eller M et al.: Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. American Journal of Cardiology 2003; 91: 1316-1322
  41. Ornish D: Statins and the soul of medicine. American Journal of Cardiology 2002; 89: 1286-1290
  42. Laroux FS, Grisham MB: Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001; 8: 283-301
  43. Faybush EM, Blanchard JF, Rawsthorne P, Bernstein CN: Generational differences in the age at diagnosis with Ibd: genetic anticipation, bias, or temporal effects. American Journal of Gastroenterology 2002; 97: 636-640
  44. Panja A, Goldberg S, Eckmann L, Krishen P, Mayer L: The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. Journal of Immunology 1998; 161: 3675-3684
  45. MacDermott RP: Alterations of the mucosal immune system in inflammatory bowel disease. Journal of Gastroenterology 1996; 31: 907-916
  46. Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Reviews of Medicine 2000; 51: 289-298
  47. Singer II, Kawka DW, Scott S et al.: Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111: 871-885
  48. Levine A, Lahav J, Zahavi I, Raz A, Dinari G: Activated protein C resistance in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 1998; 26: 172-174
  49. Menchen LA, Colon AL, Moro MA et al.: N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sciences 2001; 69: 479-491
  50. Franchimont D, Bouma G, Galon J et al.: Adrenal cortical activation in murine colitis. Gastroenterology 2000; 119: 1560-1568
  51. Leung MK, Dissous C, Capron A et al.: Schistosoma Mansoni: The Presence and Potential Use of Opiate-Like Substances. Exp Parasit 1995; 81: 208-215
  52. Goumon Y, Casares F, Pryor S et al.: Ascaris Suum, an Internal Parasite, Produces Morphine. Journal of Immunology 2000; 165: 339-343
  53. Zhu W, Baggerman G, Secor WE et al.: Dracunculus medinensis and Schistosoma mansoni contain opiate alkaloids. Annals of Tropical Medicine and Parasitology 2002; 96: 309-316
  54. Kashem A, Endoh M, Yano N, Yamauchi F, Nomoto Y, Sakai H: Expression of inducible-NOS in human glomerulonephritis: the possible source is infiltrating monocytes/macrophages. Kidney International 1996; 50: 392-399
  55. Kroencke KD, Fehsel K, Kolb-Bachofen V: Inducible nitric oxide synthase in human diseases. Clinical and Experimental Immunology 1998; 113: 147-156
  56. McCartney-Francis NL, Song X, Mizel DE, Wahl SM: Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. Journal of Immunology 2001; 166: 2734-2740
  57. Ueki Y, Miyake S, Tominaga Y, Eguchi K: Increased nitric oxide levels in patients with rheumatoid arthritis. Journal of Rheumatology 1996; 23: 230-236
  58. Grabowski PS, Wright PK, Van ”t Hof RJ, Helfrich MH, Ohshima H, Ralston SH: Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. British Journal of Rheumatology 1997; 36: 651-655
  59. Negrao AB, Deuster PA, Gold PW, Singh A, Chrousos GP: Individual reactivity and physiology of the stress response. Biomedicine and Pharmacotherapy 2000; 54: 122-128
  60. Lutgendorf S, Logan H, Kirchner HL et al.: Effects of relaxation and stress on the capsaicin-induced local inflammatory response. Psychosomatic Medicine 2000; 62: 524-534
  61. Levine JD, Moskowitz MA, Basbaum AI: The contribution of neurogenic inflammation in experimental arthritis. Journal of Immunology 1985; 135: 843s-847s
  62. Bateman AC, Turner SM, Thomas KS et al.: Apoptosis and proliferation of acinar and islet cells in chronic pancreatitis: evidence for differential cell loss mediating preservation of islet function. Gut 2002; 50: 542-548
  63. Yoon JW, Jun HS: Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Annals of the New York Academy of Sciences 2001; 928: 200-211
  64. Kleemann R, Rothe H, Kolb-Bachofen V et al.: Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Letters 1993; 328: 9-12
  65. Steiner L, Kroncke K, Fehsel K, Kolb-Bachofen V: Endothelial cells as cytotoxic effector cells: cytokine-activated rat islet endothelial cells lyse syngeneic islet cells via nitric oxide. Diabetologia 1997; 40: 150-155
  66. Kroncke KD, Fehsel K, Sommer A, Rodriguez ML, Kolb-Bachofen V: Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biological Chemistry 1995; 376: 179-185
  67. Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH: Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type diabetes. Journal of Internal Medicine 2001; 250: 415-421
  68. de la Torre JC, Stefano GB: Evidence That Alzheimer”s Disease Is a Microvascular Disorder: The Role of Constitutive Nitric Oxide. Brain Res Rev 2000; 34: 119-136
  69. Stefano GB, Prevot V, Cadet P, Dardik I: Vascular Pulsations Stimulating Nitric Oxide Release During Cyclic Exercise May Benefit Health: a Molecular Approach. International Journal of Molecular Medicine 2001; 7: 119-129
  70. Hull M, Strauss S, Berger M, Volk B, Bauer J: The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer’s disease. Behavioral Brain Research 1996; 78: 37-41
  71. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. Journal of Immunology, 2005; 175: 7357-62.
  72. Zhu W, Mantione KJ, Shen L et al. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: CYP2D6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Medical Science Monitor, 2005; 11: BR397-BR404.
  73. Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. Journal of Immunology, 2003; 170: 5118-23.
  74. Cadet P, Mantione KJ, Zhu W, Kream RM, Sheehan M, Stefano GB. A functionally coupled mu3-like opiate receptor/nitric oxide regulatory pathway in human multi-lineage progenitor cells. Journal of Immunology, 2007; 179: 5839-44.
  75. Zhu W, Bilfinger TV, Baggerman G, Goumon Y, Stefano GB. Presence of endogenous morphine and morphine 6 glucuronide in human heart tissue. International Journal of Molecular Medicine, 2001; 7: 419-22.
  76. Bianchi E, Alessandrini C, Guarna M, Tagliamonte A. Endogenous codeine and morphine are stored in specific brain neurons. Brain Res, 1993; 627: 210-5.
  77. Bianchi E, Guarna M, Tagliamonte A. Immunocytochemical localization of endogenous codeine and morphine. Adv Neuroimmunol, 1994; 4: 83-92.
  78. Bianchi E, Alessandrini C, Guarna M, Tagliamonte A. Endogenous codeine and morphine are stored in specific brain neurons. Brain Research, 1993; 627: 210-5.
  79. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C. Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain, 2006; 123: 294-305.
  80. Guarna M, Ghelardini C, Galeotti N, Stefano GB, Bianchi E. Neurotransmitter role of endogenous morphine in CNS. Medical Science Monitor, 2005; 11: RA190-RA193.
  81. Neri C, Ghelardini C, Sotak B et al. Dopamine is necessary to endogenous morphine formation in mammalian brain in vivo. J Neurochem, 2008; 106: 2337-44.
  82. Gintzler AR, Levy A, Spector S. Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide morphine-like compound in the central nervous system. Proc Natl Acad Sci USA, 1976; 73: 2132-6.
  83. Gintzler AR, Gershon MD, Spector S. A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain. Science, 1978; 199: 447-8.
  84. Atmanene C, Laux A, Glattard E et al. Characterization of human and bovine phosphatidylethanolamine-binding protein (PEBP/RKIP) interactions with morphine and morphine-glucuronides determined by noncovalent mass spectrometry. Med Sci Monit, 2009; 15: BR178-BR187.
  85. Goumon Y, Weeks BS, Cadet P, Stefano GB. Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. Mol Brain Res, 2000; 81: 177-80.
  86. Muller A, Glattard E, Taleb O, Kemmel V, Laux A, Miehe M, Delalande F, Roussel G, Van Dorsselaer A, Metz-Boutigue MH, Aunis D, Goumon Y. Endogenous morphine in SH-SY5Y cells and the mouse cerebellum. PloS ONE. Last updated: 2008 Feb [cited
  87. Zhu W, Mantione KJ, Shen L, Stefano GB. In vivo and in vitro L-DOPA exposure increases ganglionic morphine levels. Medical Science Monitor, 2005; 11: MS1-MS5.
  88. Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells: An evidence-based model. Medical Science Monitor, 2006; 12: RA207-RA219.
  89. Zhu W, Mantione KJ, Casares FM et al. Alcohol-, nicotine-, and cocaine-evoked release of morphine from invertebrate ganglia: Model system for screening drugs of abuse. Medical Science Monitor, 2006; 12: BR155-BR161.
  90. Zhu W, Mantione KJ, Shen L, Lee B, Stefano GB. Norlaudanosoline and nicotine increase endogenous ganglionic morphine levels: Nicotine addiction. Cell Mol Neurobiol, 2006; 26: 1037-45.
  91. Zhu W, Mantione KJ, Casares FM, Sheehan MH, Kream RM, Stefano GB. Cholinergic regulation of endogenous morphine release from lobster nerve cord. Med Sci Monit, 2006; 12: BR295-BR301.
  92. Zhu W, Mantione K, Kream RM, Stefano GB. Alcohol-, Nicotine-, and Cocaine-Evoked Release of Morphine from Human White Blood Cells: Substances of Abuse Actions Converge on Endogenous Morphine Release. Medical Science Monitor, 2006; 12: BR350-BR354.
  93. Zhu W, Mantione KJ, Kream RM, Cadet P, Stefano GB. Cholinergic regulation of morphine release from human white blood cells: evidence for a novel nicotinic receptor via pharmacological and microarray analysis. Int J Immunopathol Pharmacol, 2007; 20: 229-37.
  94. Zhu W, Esch T, Kream RM, Stefano GB. Converging cellular processes for substances of abuse: endogenous morphine. Neuro Endocrinol Lett, 2008; 29: 63-6.
  95. Kream RM, Sheehan M, Cadet P et al. Persistence of evolutionary memory: Primordial six-transmembrane helical domain mu opiate receptors selectively linked to endogenous morphine signaling. Medical Science Monitor, 2007; 13: SC5-SC6.
  96. Zhu W, Cadet P, Mantione KJ, Kream RM, Stefano GB. Response to Comment on “Human White Blood Cells Synthesize Morphine: CYP2D6 Modulation”. Journal of Immunology, 2006; 176: 5704.
  97. Kream RM, Liu NJ, Zhuang M et al. Synthesis and pharmacological analysis of a morphine/substance P chimeric molecule with full analgesic potency in morphine-tolerant rats. Med Sci Monit, 2007; 13: BR25-BR31.
  98. Stefano GB, Bianchi E, Guarna M et al. Nicotine, alcohol and cocaine coupling to reward processes via endogenous morphine signaling: The dopamine-morphine hypothesis. Med Sci Monit, 2007; 13: RA91-102.
  99. Stefano GB, Kream RM. Endogenous morphine synthetic pathway preceded and gave rise to catecholamine synthesis in evolution (Review). Int J Mol Med, 2007; 20: 837-41.
  100. Ghelardini C, Galeotti N, Vivoli E et al. Molecular interaction in the mouse PAG between NMDA and opioid receptors in morphine-induced acute thermal nociception. J Neurochem, 2008; 105: 91-100.
  101. Kream RM, Stefano GB. Homeopathic ethanol. Med Sci Monit, 2008; 14: SC11-SC13.
  102. Mantione KJ, Cadet P, Zhu W et al. Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition. Addict Biol, 2008; 13: 118-23.
  103. Stefano GB, Kream RM, Mantione KJ et al. Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology. Semin Cancer Biol, 2008; 18: 199-210.
  104. Stefano GB, Kream R. Endogenous opiates, opioids, and immune function: evolutionary brokerage of defensive behaviors. Semin Cancer Biol, 2008; 18: 190-8.
  105. Stefano GB, Kream RM, Esch T. Revisiting tolerance from the endogenous morphine perspective. Med Sci Monit, 2009; 15: RA189-RA198.
  106. Stefano GB, Kream RM. Dopamine, morphine, and nitric oxide: An evolutionary signaling triad. CNS Neuroscience & Therapeutics, 2009; In Press.
  107. Hiripi L, Stefano GB. Dopamine inhibition of tryptophane hydroxylase in molluscan nervous tissue homogenates: evidence for intracellular site of action. Life Sci, 1980; 27: 1205-9.
  108. Stefano GB, Hall B, Makman MH, Dvorkin B. Opioid inhibition of dopamine release from nervous tissue of Mytilus edulis and Octopus bimaculatus. Science, 1981; 213: 928-30.
  109. Stefano GB, Catapane EJ, Aiello E. Dopaminergic agents: Influence on serotonin in the molluscan nervous system. Science, 1976; 194: 539-41.
  110. Stefano GB, Scharrer B. Endogenous morphine and related opiates, a new class of chemical messengers. Adv Neuroimmunol, 1994; 4: 57-68.
  111. Stefano GB, Scharrer B, Fricchione GL. Endogenous morphine and the physiological significance of tolerance in amplification brain phenomena. In review, 1996;
  112. Stefano GB, Scharrer B, Smith EM et al. Opioid and opiate immunoregulatory processes. Crit Rev in Immunol, 1996; 16: 109-44.
  113. Lee CS, Spector S. Changes of endogenous morphine and codeine contents in the fasting rat. J Pharmacol Exp Ther, 1991; 257: 647-50.
  114. Marrazzi MA, Luby ED, Kinzie J, Munjal ID, Spector S. Endogenous codeine and morphine in anorexia and bulimia nervosa. Life Sci, 1997; 60: 1741-7.
  115. Brix-Christensen V, Tonnesen E, Sanchez RG, Bilfinger TV, Stefano GB. Endogenous morphine levels increase following cardiac surgery as part of the antiinflammatory response? Int J Cardiol, 1997; 62: 191-7.
  116. Mantione K, Hong R, Im R et al. Effects of cold stress on morphine-induced nitric oxide production and mu-opiate receptor gene expression in Mytilus edulis pedal ganglia. Neuroendocrinol Lett, 2003; 24: 68-72.
  117. Cadet P, Zhu W, Mantione K, Baggerman G, Stefano GB. Cold stress alters Mytilus edulis pedal ganglia expression of m opiate receptor transcripts determined by real-time RT-PCR and morphine levels. Brain Research: Molecular Brain Research, 2002; 99: 26-33.
  118. Narita M, Kaneko C, Miyoshi K et al. Chronic Pain Induces Anxiety with Concomitant Changes in Opioidergic Function in the Amygdala. Neuropsychopharmacology, 2006; 31: 739-50.
  119. Madbouly KM, Senagore AJ, Delaney CP. Endogenous morphine levels after laparoscopic versus open colectomy. Br J Surg, 2010; 97: 759-64.
  120. Guarna M, Bianchi E, Bartolini A et al. Endogenous morphine modulates acute thermonociception in mice. J Neurochem, 2002; 80: 271-7.
  121. Brix-Christensen V, Goumon Y, Tonnesen E, Chew M, Bilfinger TV, Stefano GB. Endogenous morphine is produced in response to cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiologica Scandinavica, 2000; 44: 1204-8.
  122. Goumon Y, Bouret S, Casares F, Zhu W, Beauvillain JC, Stefano GB. Lipopolysaccharide increases endogenous morphine levels in rat brain. Neuroscience Letters, 2000; 293: 135-8.
  123. Stefano GB, Leung MK, Bilfinger TV, Scharrer B. Effect of prolonged exposure to morphine on responsiveness of human and invertebrate immunocytes to stimulatory molecules. J Neuroimmunol, 1995; 63: 175-81.
  124. Bilfinger TV, Kushnerik V, Bundz S, Liu Y, Stefano GB. Evidence for morphine downregulating immunocytes during cardiopulmonary bypass in a porcine model. Int J Cardiol, 1996; 53: S39-S46.
  125. Brix-Christensen V, Tonnesen E, Sanchez RG, Bilfinger TV, Stefano GB. Endogenous morphine levels increase following cardiac surgery as part of the antiinflammatory response? Int J Cardiol, 1997; 62: 191-7.
  126. Bilfinger TV, Stefano GB. Downregulating the diffuse inflammatory potential following surgery-Preface. Int J Cardiol, 1998; 64: S1.
  127. Ziegler MG, Bao X, Kennedy BP, Joyner A, Enns R. Location, development, control, and function of extraadrenal phenylethanolamine N-methyltransferase. Ann NY Acad Sci, 2002; 971: 76-82.
  128. Souto M, Mariani ML. Immunochemical localization of chromaffin cells during the embryogenic migration. Biocell, 1996; 20: 179-84.
  129. Kubovcakova L, Micutkova L, Bartosova Z, Sabban EL, Krizanova O, Kvetnansky R. Identification of phenylethanolamine N-methyltransferase gene expression in stellate ganglia and its modulation by stress. J Neurochem, 2006; 97: 1419-30.
  130. Cadet P, Zhu W, Mantione K et al. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson”s patients. Int J Mol Med, 2003; 12: 485-92.
  131. Goumon Y, Stefano GB. Identification of morphine in the rat adrenal gland. Mol Brain Res, 2000; 77: 267-9.
  132. Goumon Y, Muller A, Glattard E et al. Identification of Morphine-6-glucuronide in Chromaffin Cell Secretory Granules. J Biol Chem, 2006; 281: 8082-9.
  133. Nakamura R, Okunuki H, Ishida S, Saito Y, Teshima R, Sawada J. Gene expression profiling of dexamethasone-treated RBL-2H3 cells: induction of anti-inflammatory molecules. Immunol Lett, 2005; 98: 272-9.
  134. Evinger MJ, Towle AC, Park DH, Lee P, Joh TH. Glucocorticoids stimulate transcription of the rat phenylethanolamine N-methyltransferase (PNMT) gene in vivo and in vitro. Cell Mol Neurobiol, 1992; 12: 193-215.
  135. Wong DL, Siddall B, Wang W. Hormonal control of rat adrenal phenylethanolamine N-methyltransferase. Enzyme activity, the final critical pathway. Neuropsychopharmacology, 1995; 13: 223-34.
  136. Kvetnansky R, Krizanova O, Tillinger A, Sabban EL, Thomas SA, Kubovcakova L. Regulation of gene expression of catecholamine biosynthetic enzymes in dopamine-beta-hydroxylase- and CRH-knockout mice exposed to stress. Ann N Y Acad Sci, 2008; 1148: 257-68.
  137. Unsworth BR, Hayman GT, Carroll A, Lelkes PI. Tissue-specific alternative mRNA splicing of phenylethanolamine N-methyltransferase (PNMT) during development by intron retention. Int J Dev Neurosci, 1999; 17: 45-55.
Source: Cover Image and Credit: Stress. By Ekaterina Zakharova. Via

You must be logged in to post a comment Login